A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
Arvinas Inc.
Myeloid Therapeutics
DualityBio Inc.
Seagen Inc.
West China Hospital
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Alaunos Therapeutics
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Elicio Therapeutics
TCR2 Therapeutics
TCR2 Therapeutics
Jonsson Comprehensive Cancer Center
University Hospital, Angers
Telix Pharmaceuticals (Innovations) Pty Limited
NextPoint Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
Tongji Hospital
Instituto do Cancer do Estado de São Paulo
Janssen Research & Development, LLC
Elevation Oncology
Zymeworks BC Inc.
Symphogen A/S
ABM Therapeutics Shanghai Company Limited
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
University of California, San Diego
Convalife (Shanghai) Co., Ltd.
ABM Therapeutics Corporation
TransThera Sciences (Nanjing), Inc.
Beijing Kejing Biotechnology Co., Ltd.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
NextCure, Inc.
Universitair Ziekenhuis Brussel
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
University of Florida
Hoffmann-La Roche
Klus Pharma Inc.
Tempest Therapeutics
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
Wellmarker Bio
Bayer